Boehringer Ingelheim, Dicerna Launch Liver Disease Collaboration

Boehringer Ingelheim and Dicerna Pharmaceuticals said today they will partner to develop new treatments for chronic liver diseases by using Dicerna’s RNA interference (RNAi)-based GalXC ™ tech platform, with an initial focus on nonalcoholic steatohepatitis (NASH).The research collaboration and license agreement could generate up to $201 million for Dicerna.Dicerna’s GalXC platform is designed to work by using RNAi to inhibit the expression of disease-causing genes by destroying